- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02828618
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST)
This study consists of three parts, whereas Part 1 and Part 2 are performed in Germany only, and Part 3 is a multinational trial.
All patients with suspicion of advanced ovarian cancer are detected in the participating study centers in a pre-screening. The study centers will register all patients with suspected ovarian cancer in a screening log. After the patients have given informed consent, they can be enrolled in different parts of the study.
TRUST-Trial: This part compares two strategies in the therapy of advanced ovarian cancer. En detail, this part of the trial will evaluate if one of two strategies of timing surgery within the therapeutic procedures may show any significant advances in terms of overall survival over the other.
Study Overview
Status
Conditions
Detailed Description
Both randomised groups are treated with surgery for complete resection following guideline recommendations and including median laparotomy, complete adhesiolysis, hysterectomy, bilateral salpingo-oophorectomy, omentectomy and (partial) resection of all affected organs (e.g. small or large bowel, peritoneum, spleen, pancreas, peritoneum, urinary tract etc.) as well as pelvic and paraaortic lymphadenectomy if indicated. Patients with significant pleural effusion (>500 mL in the right chest or any pleural effusion in the left chest, assessed either through ultrasound or CT scan) need to undergo video assisted thoracoscopy or open assessment of the pleura prior or during debulking surgery to detect and if possible remove intrathoracic disease.
Group 1: Primary debulking surgery Patients allocated to the primary debulking group undergo surgery followed by 6 cycles of platinum and taxane based chemotherapy.
Recommended systemic treatment Group 1:
It is recommended to start systemic treatment after sufficient regeneration from surgery [45], which will be ideally 2 to 6 weeks (but at the latest 8 weeks) after surgery. The following treatments are recommended:
- Participation in a prospective randomized trial, as long as participation is possible in case of randomization in either arm of the current study
- Carboplatin AUC 5-6 / paclitaxel 175 mg/m² q21 / bevacizumab 15mg/KG q21, 6 cycles followed by bevacizumab maintenance therapy for a total of 15 months or until disease progression.
- Carboplatin AUC 5-6 / paclitaxel 175 mg/m² q21, 6 cycles. Substitution of paclitaxel by docetaxel (75mg/m²) in cases of contraindications to paclitaxel is possible. Maintenance/consolidation therapy inside prospective trials or according to national standard treatments is allowed. Additional treatment outside prospective studies is not recommended.
- Carboplatin AUC 5 - 6, q21 , 6 cycles in the case of contraindications of combination chemotherapy
Group 2: Interval debulking surgery Patients allocated to the interval debulking surgery group undergo biopsy to confirm ovarian cancer and then 3 cycles of neoadjuvant preoperative platinum and taxane based chemotherapy. Then interval debulking surgery is performed followed by 3 cycles of postoperative platinum and taxane based chemotherapy
Recommended systemic treatment Group 2:
It is recommended to start systemic treatment as soon as possible after biopsy confirmation of ovarian cancer.
The following treatments are recommended for neoadjuvant chemotherapy:
- Participation in a prospective randomized trial, as long as participation is possible in case of randomization in either arm of the current study
- Carboplatin AUC5-6 / paclitaxel 175 mg/m² q21, 3 cycles. Substitution of paclitaxel by docetaxel (75mg/m²) in cases of contraindications to paclitaxel is possible.
- Carboplatin AUC 5-6, q21 , 3 cycles in the case of contraindications of combination chemotherapy
It is recommended to start postoperative chemotherapy after sufficient regeneration from interval debulking surgery, which will be ideally 2 to 6 weeks after surgery. The following treatments are recommended:
- Participation in a prospective randomized trial, as long as participation is possible in case of randomization in either arm of the current study
- Carboplatin AUC 5-6 / paclitaxel 175 mg/m² q21 / bevacizumab 15mg/KG q21, 3 cycles followed by bevacizumab maintenance therapy for a total of 15 months or until disease progression.
- Carboplatin AUC5-6 / paclitaxel 175 mg/m² q21, 3 cycles. Substitution of paclitaxel by docetaxel (75mg/m²) in cases of contraindications to paclitaxel is possible. Maintenance/consolidation therapy inside prospective trials or according to national standard treatments is allowed. Additional treatment outside prospective studies is not recommended.
- Carboplatin AUC 5-6, q21 , 3 cycles in the case of contraindications of combination chemotherapy
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, A-1090
- Medical University of Vienna
-
-
-
-
-
Copenhagen, Denmark, 2100
- University Hospital, Rigshospitalet
-
-
-
-
-
Bordeaux, France
- Institut Bergonie
-
Paris, France
- Hôpital Européen Georges Pompidou (HEGP)
-
Villejuif, France, 94805
- Institute Gustave Roussy
-
-
-
-
-
Berlin, Germany, 13353
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie
-
Dresden, Germany, 01307
- Universitätsklinikum Carl Gustav Carus Dresden, Klinik & Poliklinik f. Frauenheilkunde & Geburtshilfe
-
Dusseldorf, Germany
- Kaiserswerther Diakonie; Florence-Nightingale-Hospital
-
Essen, Germany, 45136
- Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gyn. Onkologie
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
-
München, Germany, 81377
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
-
München, Germany, 81675
- Klinikum rechts der Isar, Frauen- und Poliklinik
-
Tübingen, Germany
- Universitätsklinikum Tübingen
-
-
-
-
-
Milano, Italy
- European Institute of Oncology; Gynecologic Cancer Surgery
-
Milano, Italy
- Fondazione IRCCS Istituto Nazionale Tumori - Milan
-
Naples, Italy
- Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli
-
-
-
-
-
Lund, Sweden, 22185
- Skåne University Hospital
-
Solna, Sweden, 17176
- Karolinska University Hospital
-
-
-
-
-
London, United Kingdom, W12 OHS
- Imperial College London, Hammersmith Hospital, Surgery&Cancer
-
-
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer FIGO stage IIIB-IV (IV only if resectable metastasis)
- Females aged ≥ 18 years
- Patients who have given their written informed consent
- Good performance status (ECOG 0/1)
- Good ASA score (1/2)
- Preoperative CA 125/CEA ratio ≥ 25 (if CA-125 is elevated)*
- If <25 and/or biopsy with non-serous, non-endometroid histology, esophago-gastro-duodenoscopy (EGD) and colonoscopy mandatory to exclude gastrointestinal primary cancer
- Assessment of an experienced surgeon, that based on all available information, the patient can undergo the procedure and the tumor can potentially be completely resected
- Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. This ANC cannot have been induced or supported by granulocyte colony stimulating factors.
- Platelet count ≥ 100 x 109/L.
- Renal function: Serum-Creatinine ≤ 1.5 x institutional upper limit normal (ULN).
Hepatic function:
- Bilirubin ≤ 1.5 x ULN.
- SGOT ≤ 3 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN.
- Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1.
Exclusion Criteria:
- Non epithelial ovarian malignancies and borderline tumors
- Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity.
- Recurrent ovarian cancer
- Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy
- Unresectable parenchymal lung metastasis, liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis
- Clinical relevant dysfunctions of blood clotting (including drug induced)
- Any significant medical reasons, age or performance status that will not allow to perform the study procedures (estimation of investigator)
- Pregnancy
- Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent
- Any reasons interfering with regular follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I PDS and chemotherapy
PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
|
PDS with maximum effort to achieve the goal of complete gross resection
6 cycles of standard chemotherapy after Primary Debuling Surgery
|
Experimental: Arm II Timing of surgery after 3 cycles of SOC CTX
3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
|
Timing of surgery after 3 cycles of standard NACT
IDS with maximum effort to achieve the goal of complete gross resection after NACT
3 more cycles (for a total of 6) of standard chemotherapy after IDS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival (OS)
Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
To compare the overall survival (OS) after primary debulking surgery (PDS) versus interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) in patients with FIGO (2014) stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma. The primary endpoint overall survival time is calculated from the date of randomization until the date of death from any cause or date of last contact (censored observation). |
Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Progression-free survival time is calculated from the date of randomization until the date of first progressive disease or death, whichever occurs first or date of last contact (censored observation).
Progressive disease is defined as clinical or imaging-detected tumor progression or death in cases without prior documented tumor progression.
|
Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Progression-free survival 2 (PFS2)
Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
PFS2 time is calculated from the date of randomization until the date of second progressive disease or death, whichever occurs first or date of last contact (censored observation).
|
Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Time to first subsequent anticancer therapy or death (TFST)
Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Time to first subsequent anticancer therapy is calculated from the date of randomization until the starting date of the first subsequent anticancer therapy or death, whichever occurs first or date of last contact (censored observation).
Maintenance treatments following a cytostatic treatment are not considered separate treatment lines.
|
Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Time to second subsequent anticancer therapy or death (TSST)
Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Time to second subsequent anticancer therapy is calculated from the date of randomization until the starting date of the second subsequent anticancer therapy or death, whichever occurs first or date of last contact (censored observation).
Maintenance treatments following a cytostatic treatment are not considered separate treatment lines.
|
Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Quality of life (QoL)
Time Frame: Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Quality of life (QoL) as measured by EORTC QLQ-C30 (Version 3), EORTC QLQ-OV28, EQ-5D-3L
|
Patients will be followed up for a minimum of 5 years after registration/randomisation or until death
|
Documentation of surgical complications
Time Frame: Patients will be followed up for 1 year after surgery or until death
|
Assessment of safety: documentation of surgical complications 28 days after surgery and 1 year after surgery.
|
Patients will be followed up for 1 year after surgery or until death
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sven Mahner, Professor MD, AGO Study Group
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- AGO-OVAR OP.7/TRUST
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on PDS (Primary Debulkdung Surgery)
-
Shanghai Gynecologic Oncology GroupRecruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaKorea, Republic of, China
-
Shanghai Gynecologic Oncology GroupXinhua Hospital, Shanghai Jiao Tong University School of Medicine; Obstetrics... and other collaboratorsNot yet recruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaChina
-
Shanghai Minimally Invasive Surgery CenterCompletedGastric Cancer | Colorectal CancerChina
-
Federation of Breast Diseases SocietiesMarmara University; Istanbul University; Abant Izzet Baysal UniversityCompleted
-
British Obesity and Metabolic Surgery SocietyCompleted
-
Northwell HealthCompletedArthroplasty | Total Knee Replacement | PatellaUnited States
-
Kevin MunroGöteborg University; University of Copenhagen; National Institute of Dental and... and other collaboratorsCompletedCleft PalateNorway, United Kingdom, Sweden, Brazil, Denmark
-
National Cancer Institute, ThailandVichaiyut HospitalWithdrawnCarcinoma Breast Stage IVThailand
-
Shanghai Gynecologic Oncology GroupFudan UniversityNot yet recruitingOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaChina
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminatedLung CancerNetherlands